Shasun Chemical reports net profit for year
Indian API manufacturer Shasun Chemicals and Drugs turned a previous loss into profit for Q4 of this year as it seeks to make a dent in the biosimilar manufacturing sector.
Large pharma to boost CMOs’ biologics business; report
CMOs are set to gain biologics business and capacity in the coming years as large pharma increasingly outsources to cut costs and speed development, according to a report published today.
Natural drug delivery system aids cancer therapeutics
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
Irish pharmaceutical company Elan says most potential investors are positive about proposal to spin-off drug delivery unit.
Cheaper insulin production proposed for emerging markets
Researchers have developed an alternative, cheaper method of producing insulin to help increase availability in emerging markets.
Cevec licenses CAP-T cell expression tech to Pevion
Cevec has exclusively licensed its transient CAP-T cell expression technology to Pevion for the manufacture and commercialisation of a protein antigen to vaccinate against an infectious disease.
Apotex launches generic Lipitor in Canada
Generics firm Apotex has launched a non-branded version of Pfizer’s mega-blockbusting cholesterol drug Lipitor in Canada
Almac teams on X-ray data analysis; US plant nears completion
Almac hopes University College Cork solid state chemistry accord will bypass crystallisation hurdles and accelerate drug development.
DSM: XD scale-up can cut drug production costs
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
CRAMS growth helps Jubilant in fiscal 2010
International demand for contract manufacturing helped India’s Jubilant Organosys finish fiscal 2010 with a quarter of growth.
DSM joins with Australian government for biologics plant
DSM Biologics has entered into a partnership with the Australian government to build a 70,000 sq ft biopharmaceutical contract manufacturing facility.
GBI, Hyprocell collaborate to offer cell line development
CMO Goodwin Biotechnology Inc (GBI) is collaborating with Hyprocell to help clients that need manufacturing services but have a sub-optimal cell line producing low concentrations.
New Xcellerex CEO targets growth in revenues, clients
The incoming Xcellerex CEO plans to move the company from validation to penetration, boosting revenues and client base, and invest in the contract manufacturing side of the business.
ACRO funds research into CROs’ role in drug development
ACRO is aiming to increase recognition and analysis of the value CROs bring to drug development, spanning their role as strategic partners throughout the process, by funding academic research.
Mircofluidics launches continuous nanocrystallisation tech
Microfluidics chose Interphex 2010 in New York, US to unveil a new processing technology that it claims can help manufacturers save time and money by switching from batch to continuous particle production.